(formatting) |
(formatting) |
||
| Line 766: | Line 766: | ||
<br> | <br> | ||
==Mental Health - Schizophrenia== <!--T:176--> | =='''Mental Health - Schizophrenia'''== <!--T:176--> | ||
===2021 [https://academic.oup.com/ntr/article/23/7/1113/6168972 A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes]=== <!--T:177--> | ===2021 [https://academic.oup.com/ntr/article/23/7/1113/6168972 A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes]=== <!--T:177--> | ||
| Line 776: | Line 775: | ||
*Citation: Pasquale Caponnetto, PhD, Jennifer DiPiazza, PhD, Jason Kim, MD, Marilena Maglia, Lyc Psych, Riccardo Polosa, MD, PhD, A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes, Nicotine & Tobacco Research, Volume 23, Issue 7, July 2021, Pages 1113–1122, 10.1093/ntr/ntab005 | *Citation: Pasquale Caponnetto, PhD, Jennifer DiPiazza, PhD, Jason Kim, MD, Marilena Maglia, Lyc Psych, Riccardo Polosa, MD, PhD, A Single-Arm, Open-Label, Pilot, and Feasibility Study of a High Nicotine Strength E-Cigarette Intervention for Smoking Cessation or Reduction for People With Schizophrenia Spectrum Disorders Who Smoke Cigarettes, Nicotine & Tobacco Research, Volume 23, Issue 7, July 2021, Pages 1113–1122, 10.1093/ntr/ntab005 | ||
*Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength. | *Acknowledgement: The authors wish also to thank PAX Labs (on June 13, 2017 the company became known as JUUL Labs) for the free supplies of JUUL e-cigarette kits and pods. At the time the research was conducted JUUL Labs were not part owned by Altria, a tobacco company. PAX Labs agreed also to supply pods for a further 3 months after the end of the pilot to participants who expressed a wish to continue using as JUUL was not available in Italy when this study has been conducted and not currently available at the 5% nicotine strength. | ||
===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]=== <!--T:179--> | ===2020 [https://www.sciencedirect.com/science/article/abs/pii/S0149763420305042?via%3Dihub The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review]=== <!--T:179--> | ||
| Line 786: | Line 783: | ||
*Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience & Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035. | *Citation: Clément Dondé, Jérôme Brunelin, Marine Mondino, Caroline Cellard, Benjamin Rolland, Frédéric Haesebaert, The effects of acute nicotine administration on cognitive and early sensory processes in schizophrenia: a systematic review, Neuroscience & Biobehavioral Reviews, Volume 118, 2020, Pages 121-133, ISSN 0149-7634, doi: 10.1016/j.neubiorev.2020.07.035. | ||
*Keywords: Schizophrenia, Nicotine, Cognition, Early sensory | *Keywords: Schizophrenia, Nicotine, Cognition, Early sensory | ||
===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]=== | ===2016: [https://truthinitiative.org/sites/default/files/media/files/2019/08/ReThinking-Nicotine_0.pdf Re-thinking nicotine and its effects]=== | ||
| Line 792: | Line 788: | ||
*Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population. | *Some subgroups, such as those with an underlying vulnerability to mental health or medical conditions, may benefit, more or less, from the use of nicotine, when compared with the general population. | ||
*Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner | *Truth Initiative / Schroeder Institute: Raymond Niaura, PhD. - This paper was also reviewed by content area experts whose feedback was included: Drs. Neal Benowitz, Peter Shields, Dorothy Hatsukami, and Ken Warner | ||
===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]=== <!--T:181--> | ===2009 [https://pubmed.ncbi.nlm.nih.gov/19328631/ Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications]=== <!--T:181--> | ||
| Line 800: | Line 795: | ||
*[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version] | *[https://sci-hub.st/10.1016/j.mehy.2009.02.017 PDF Version] | ||
*Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631. | *Citation: Conway JL. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications. Med Hypotheses. 2009 Aug;73(2):259-62. doi: 10.1016/j.mehy.2009.02.017. Epub 2009 Mar 27. PMID: 19328631. | ||
===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]=== | ===2002 [https://pubmed.ncbi.nlm.nih.gov/12769614/ Nicotinic treatment for cognitive dysfunction]=== | ||
edits